Research Article

Evaluation of Demographic, Clinical and Laboratory Features of Patients with Systemic Lupus Erythematosus in Kermanshah

Zahra Mahmoudi [ID][1], Mahsa Nikjoo [ID][2], Alireza Rezaiemanesh [ID][1], Majid Ahmadi [ID][3] and Daryoush Pourmand [ID][4, *]

[1]Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
[2]Shohada Harsin Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
[3]Department of Internal Diseases, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
[4]Department of Laboratory Science, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran

[*]*Corresponding author*: Department of Laboratory Science, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: pourmand_d@yahoo.com

Abstract

Background: Systemic lupus erythematosus (SLE) is a worldwide autoimmune disease. The disease has different etiologies, clinical and laboratory symptoms between different geographical and racial groups, and sufficient knowledge of the type of symptoms in each region can play a proper role in diagnosis and treatment.

Objectives: This study was performed to evaluate demographic, clinical and laboratory features of patients with systemic lupus erythematosus in Kermanshah.

Methods: This study is descriptive, analytical and cross-sectional. The files of 150 patients with lupus during 2016 - 2018 in Imam Reza hospital in Kermanshah were reviewed.

Results: Data analysis showed that patients at the time of referral were with musculoskeletal symptoms 37.3% (56 individuals), cutaneous-mucosal 32% (48 individuals), constitutional 51.3% (77 individuals), renal 62% (93 individuals), cardiac 6.7% (10 individuals), neurological manifestations 17.3% (26 individuals), pulmonary involvement 37.3% (56 individuals), and Hematological 71.3% (107 individuals). The anti-nuclear antibody (ANA) in 60% (90 individuals), anti-double strand DNA Antibody (anti-ds DNA) in 35.4% (53 individuals), C-reactive protein (CRP) in 44.6% (67 individuals), lower level of normal C3 and C4 in 33.3% (50 individuals) and 11.3% (17 individuals), respectively, lupus anticoagulant in 13.3% (20 individuals), antibody citrullinated peptide anti-cyclic (anti-CCP) in 14.9% (22 individuals), anticardiolipin IgM and IgG, in 6% (9 individuals) and 9.3% (14 individuals) of patients respectively were observed. Also, anemia was observed in 34% (51 individuals), leukopenia in 22% (33 individuals), and thrombocytopenia in 30.7% (46 individuals). Abnormal ESR (erythrocyte sedimentation rate) was seen in 59.3% (89 individuals) of patients. Leukopenia in men and positive CRP in women were more common (P = 0.014, P = 0.004).

Conclusions: Despite the diverse clinical and laboratory manifestations of SLE in different racial and geographical groups, paying attention to these differences in each region can effectively diagnose the disease. As in this study, hematological manifestations had a higher percentage in the population of lupus patients in Kermanshah.

Keywords: Systemic Lupus Erythematosus, Rheumatology, Clinical Signs, Laboratory Features

1. Background

Systemic lupus erythematosus (SLE) is an autoimmune disease with global distribution and great diversity among different ethnic and geographical groups (1). Organs, tissues, and cells are damaged by the deposition of immune complexes in this disease (2).

Gender is so important in the susceptibility to SLE that it affects young women of childbearing age with a female-to-male sex ratio of 9 to 1 (3, 4). This ratio is lower in children before puberty and in postmenopausal women (5). In addition to differences in susceptibility to the disease between men and women, clinical and paraclinical manifestations of this disease differ between men and women (1). The higher prevalence of SLE in women indicates the effect of sex hormones on the manifestation of the disease, and this hormonal effect on the disease has also been seen in animal models of the disease (6). The disease is more common and more severe in blacks and Hispanics and is more common in the second to fourth decades of a person's life (7).

Definitive diagnosis is made based on a set of signs and

symptoms. Kidney, psycho-neurological, cardiovascular, coagulation and blood disorders cause the death in these patients. Scientific advances in treatment and supportive care have led to more prolonged survival in patients with SLE. The 5-year survival, which was about 50 percent in the 1950s, increased to 90 percent in the 1990s (8). Internal and laboratory symptoms usually appear after joint and skin disorders (9-11).

The disease has unknown causes and different clinical and laboratory manifestations, and in its images, many differences between different racial and geographical groups have been observed. (12).

Iran is composed of different racial groups (13). Due to the different prevalence of the disease in different racial populations as well as different clinical manifestations of the disease, we examined the demographic characteristics, clinical signs, and paraclinical findings of patients with SLE in Imam Reza Hospital in Kermanshah during 2016 - 2018.

2. Methods

This study is descriptive, analytical and cross-sectional. In this study, the files of 150 patients referred to Imam Reza hospital in Kermanshah during the years 2016 - 2018 who have the inclusion criteria were reviewed. All research units must have the following characteristics:

(1) A rheumatologist has recorded the diagnosis of lupus in their medical records based on the EULAR / ACR classification criteria (14).

(2) They had no history of other rheumatic and underlying diseases.

To collect information, the files of patients referred to the hospital were studied. Required information includes: demographic characteristics (age, sex), clinical signs (cardiac, neurological, cutaneous-mucosal, musculoskeletal, pulmonary, temperamental, renal, and blood), and paraclinical findings (hemoglobin level, white blood cell count and platelet count) and immunological and serological tests including antinuclear antibody (ANA), anti-ds DNA, CRP, C3, C4, lupus anticoagulant, anti-cyclic citrullinated peptide antibody (Anti-CCP) and anticardiolipin IgM and IgG, as well as ESR test, which was collected by a checklist.

2.1. Statistics

After collecting the required information, the data were statistically analyzed using SPSS software version 16. Frequency and ratio were used to represent qualitative variables, and the mean and the standard deviation were used for quantitative variables. The relationship between

gender and clinical signs and paraclinical findings was assessed using the Chi-square test. Significance level (P-value < 0.05) is considered.

3. Results

In this study, the records of 150 patients with SLE were examined, of which 23 (15.3%) were male and 127 (84.7%) were female. The mean age of the patients was 34.9 ± 11 years. Blood involvement with a frequency of 71.3% had the highest frequency among clinical symptoms (Figure 1). Kidney involvement was higher in 65.2% of men and blood involvement in 73.2% of women (Table 1).

Table 1. Comparison of the Frequency of Clinical Symptoms in Patients with SLE by Gender [a]

Clinical Signs	Female (N = 127)	Male (N = 23)	P-Value
Cardiac	9 (7.1)	1 (4.3)	0.628
Neurological	22 (17.3)	4 (17.4)	0.994
Cutaneous-mucosal	37 (29.1)	11 (47.8)	0.077
Musculo-skeletal	50 (39.4)	6 (26.1)	0.226
Pulmonary	47 (37)	9 (39.1)	0.846
Constitutional	65 (51.2)	12 (52.2)	0.930
Renal	78 (61.4)	15 (65.2)	0.730
Hematological	93 (73.2)	14 (60.9)	0.228

[a] Values are expressed as No. (%).

ANA positive was observed in 90 patients (60%) and abnormal levels of anti-ds DNA (> 50 units per ml) were observed in 53 patients (35.4%). In this study, patients were also evaluated for CRP test, of which 67 (44.6%) were positive.

The mean level of C3 complement in 150 patients was 100.63 ± 42.68 mg/dL, and the mean level of C4 complement was 20.89 ± 16.44 mg/dL. The minimum levels of C3 and C4 were 10 and 1, respectively, and the maximum was 210 and 125, respectively. Low C3 level (< 80) and low C4 level (< 10) was observed in 33.3% and 11.3% of patients, respectively. Lupus anticoagulant was observed in 20 patients (13.3%), anti-CCP in 22 patients (14.7%), anti-cardiolipin IgM in 9 patients (6%) and anti-cardiolipin IgG in 14 patients (9.3%).

In this study, 33 patients (22%) had leukopenia (white blood cells less than 4,000 per cubic millimeter), and 17 patients (11.3%) had leukocytosis (white blood cells more than 11,000 per cubic millimeter). 104 patients (69.3%) had thrombocytopenia (platelets less than 150,000 per cubic millimeter) and 51 patients (34%) had anemia (hemoglobin less than 10 mg/dL). 13.3% of patients had severe anemia (hemoglobin less than 8 mg/dL). In this study, the ESR of

Figure 1. Relative frequency of each clinical symptom in patients with systemic lupus erythematosus in Kermanshah

more than 30 mm/h was considered higher than normal and abnormal values were observed in 59.3% of patients (Table 2).

Leukopenia in men and positive CRP in women was more common (P = 0.014, P = 0.004) (Table 3).

4. Discussion

SLE is a systemic disease that can be complicated by the irreversible consequences of the disease process or medications' side effects (15). In the past, the disease often led to death due to lack of treatment. The discovery of corticosteroids and the use of these drugs and immunosuppressive drugs increased the life expectancy of patients with SLE. However, while these drugs increase patients' life expectancy, they also increase patients' physical disability (16).

SLE usually begins at puberty. The mean age of patients in previous studies was 40.3 ± 12.4 in Turkey, 31 ± 2.1 in China, 19 in Taiwan and 27 in Mexico. (6, 17, 18). In the present study, the mean age at onset was 34.9 ± 11 years. In previous studies in Iran, the mean age of patients with SLE in Isfahan was 31.6 ± 10 (12), in Tehran 29 ± 9.9 and in Ahvaz 26.4 ± 14.2 years (19). According to the results of the present study, it seems that the age of onset of the disease was slightly higher in individuals, which was contrary to some results obtained from the above tasks, but it is similar to some of them, and in general, it can be considered that SLE occurs in the second, third and sometimes fourth decades of a person's life.

The disease is more common in women than men, so that in similar studies, especially in different races in the United States, the ratio of women to men ranged from 4 to 1 to 13.6 to 1. This ratio has been reported in other studies in Iran 10, China 11.4, Greece 7, Saudi Arabia 5.5, and Malaysia 10.17 (6, 20-22). In our study, the population of sick women was 5.5 times that of men.

In the present study, anemia was observed in 34% of patients. In a study conducted by Yaghoubi and Fathi in Ahvaz on 30 patients with lupus, anemia with hemoglobin less than 10 mg/dL was reported in 56.6% (17 patients) (19). In the study of Tabarestani et al. in Mashhad, which was performed on 96 patients, there was anemia in 79% of patients (23). Our study's result is different from the results of the two mentioned studies, and the probable reason for this difference could be a difference in the sample size.

The prevalence of leukopenia in China in a study of 51 patients was 16%, in Taiwan 47% in a study of 72 patients, in Jamaica 22.7% in a study of 150 patients and in Iran 28.5% in a study of 239 patients (20). In other studies in Iran, in the study of Tabarestani et al. in 96 patients with lupus was 32.3% (23), and in the study of Yaghoubi and Fathi in 53 patients with lupus, this frequency was 53.3% (19). In the study of Seyed Bonakdar et al. in Isfahan, 19% of patients (200 lupus patients over 16 years old) had leukopenia (12). In our research, this frequency was 22%, which is different from most of the mentioned studies. But it is similar to the result of the study conducted in Jamaica and is similar to the result of the Isfahan study. The proximity of the number of samples studied can be a reason for the similarity of

the results, and vice versa, the small statistical population in most other studies, can be considered the reason for the difference between their results and the current study conducted in Kermanshah.

In our study, 17 patients (11.3%) had leukocytosis, while in previous studies, no cases of leukocytosis have been reported. Only in one study aimed at determining clinical and laboratory symptoms in patients with lupus erythematosus discoid in Shiraz, 2% leukocytosis was reported (24).

The rate of thrombocytopenia in the patients of our study was 30.7%, while in other studies, in Iran was 19.2% (20), in Jamaica was 7.3% (25), in Taiwan was 21% (18), in China was 25% (6), in Shiraz was zero (24), in Isfahan was 9% (12) and in another study in Mashhad was 15.2% (23).

In patients with SLE, the CRP test is often not positive, but in cases where there is an active infection, the CRP test is positive, and its levels increase (26). In our study, 44.6% of patients were CRP positive. In other studies, the rate of positive CRP cases in Shiraz was zero (24), in Kerman was 27.9% (27), in Isfahan was 25% (12) and in Ahvaz was 31.5% (19).

In a study by Amini et al. in Kerman, on 326 patients with SLE, 214 patients (65.6%) had high ESR. In our study, 116 patients (35.5%) showed ESR less than 50 mm/h, 71 patients (21.7%) showed ESR between 50 and 100, and 27 patients (8.2%) showed ESR above 100 (27). In the Ahwaz study, 89.2% of patients showed ESR above 50 mm/h (19). In the study of Tabarestani et al. in Mashhad, 84.8% of the patients had a high ESR (23). In Isfahan, ESR above 30 mm^3 per hour was observed in 55% of patients (12). In our study, ESR above 30 mm^3 per hour was observed in 59.3% of patients.

The results of our study showed that 60% of patients had positive ANA test. In previous studies, the rate of ANA positive cases has been reported in Jamaica at 90.7%, in Taiwan at 97%, and in China at 98% (6, 18, 25). In studies in Iran, in Kerman, it was 71.4% (27), in Mashhad was 98.8% (23), in Ahvaz was 81.2% (19) and in Isfahan was 92% (12).

Anti-double-stranded DNA antibodies were higher than usual in 35.4% of the patients in our study. Abnormality of this antibody in other previous studies in Ahvaz was 92.3% (19), in Isfahan was 81% (12), in Kerman was 56.7% (27), in China was 67% (6), in Taiwan was 60% (18), in Jamaica was 63.3% (25) and in Saudi Arabia was 65% (28). The high level of anti-double-stranded DNA antibodies in our patients was lower than other statistics.

The presence of anti-phospholipids was seen in more than 20% of patients with SLE. Lupus anticoagulants and anticardiolipin are two types of phospholipid autoantibodies (10).

In the present study, the prevalence of lupus anticoagulants was 13.3%. Also, the prevalence of anticardiolipin IgM

was 6% and anticardiolipin IgG was 9.3%. In Ahvaz, with a review of 45 patients with lupus, anticardiolipin IgM and IgG were reported to be 25% and 23%, respectively (29). In Kerman, anticardiolipin was reported in 7.9% (26 patients) of the study population (27). In Isfahan, the prevalence of lupus anticoagulant was 27.5% (12). In a study in Jamaica of 150 patients, anticardiolipin was observed in 3.5% (8 patients) and lupus anticoagulant was observed in 3.3% (5 patients) (25).

The results of our study were different and less than other studies in terms of ANA, anti-ds DNA and anti-phospholipids. The reason for this difference is that the patients we studied mostly had a history of several years of disease and were often treated, which may have reduced the level of these antibodies in patients with the effect of therapeutic drugs and immunosuppressants.

In this study, the most common clinical symptoms observed at the beginning of the visit were blood symptoms (anemia, thrombocytopenia, and leukopenia) with a frequency of 71.3%. In a study in China, the most common clinical symptom was musculoskeletal involvement (arthritis) with 86% (6), in Taiwan, skin involvement (malar rash) with 61% (18), and in Jamaica, musculoskeletal involvement (arthritis) with 94% (25). In the study of Akbarian et al., which was performed on 2143 patients in Tehran, the most common symptoms were musculoskeletal involvement (82.5%) (13). In the study of Saghafi et al., the most common symptoms were neuropsychological symptoms (30). In the study of Seyed Bonakdar et al., the most common symptom was musculoskeletal symptoms with 65% frequency (12).

A study of 65 patients with SLE in Saudi Arabia reported that the most common clinical sign was arthralgia or arthritis (28). In a study by Font et al., skin involvement was more common in men with lupus than in women, and specifically, the discoid rash was twice as common in men as in women. Also, the prevalence of skeletal involvement at the onset of the disease was lower in men than women (31). In the study of Ebrahimpour et al., skin manifestations were significantly more common in men (35.7% vs. 26.7% with P = 0.004), but musculoskeletal involvement was significantly less reported in men (38.7% in men versus 48.7% in women with P = 0.005) (32). While in our study, the most common clinical symptom in men was renal involvement with 65.2%, and in contrast, blood involvement with 73.2% was the most common clinical symptom in women. But in general, there was no significant difference between men and women in the manifestations of the disease. Studies in Kerman (27) and Ahvaz (19) also reported patients' most common clinical symptoms with mucosal skin involvement.

In our study, the presence of leukopenia was signifi-

Table 2. Results of Paraclinical Characteristics of Patients with A Diagnosis of SLE

Variables	Frequency, No. (%)
Hemoglobin	
Less than 10 mg per deciliter	51 (34)
More than 10 mg per deciliter	99 (66)
WBC	
Less than 4000 per cubic millimeter	33 (22)
More than 4000 per cubic millimeter	117 (78)
PLT	
Less than 150,000 per cubic millimeter	46 (30.7)
More than 150,000 per cubic millimeter	104 (69.3)
ESR	
< 30	61 (40.7)
≥ 30	89 (59.3)
CRP	
Positive	67 (44.6)
Negative	83 (53.3)
IgM anticardiolipin	
Positive	9 (6)
Negative	141 (94)
IgG anticardiolipin	
Positive	14 (9.3)
Negative	136 (90.7)
ANA	
Positive	90 (60)
Negative	60 (40)
Anti-ds DNA	
< 50	97 (64.6)
≥ 50	53 (35.4)
C3	
< 80	50 (33.3)
≥ 80	100 (66.7)
C4	
< 10	17 (11.3)
≥ 10	133 (88.7)
Lupus anticoagulants	
Positive	20 (13.3)
Negative	130 (86.7)
Anti-CCP	
Positive	22 (14.7)
Negative	128 (85.3)

Abbreviations: WBC, white blood cell; PLT, platelet; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ANA, anti-nuclear antibody; Anti-ds DNA, anti-double strand DNA Antibody; C3, complement 3; C4, complement 4; Anti-CCP, Anti-Cyclic citrulinated peptide.

Table 3. Relationship Between Laboratory Variables and Gender

Variables	Female (%)	Male (%)	P-Value
ANA			0.47
Positive	58.3	66.7	
Negative	41.7	33.3	
Anti-ds ANA			0.558
< 50	65.6	59.1	
≥ 50	34.4	40.9	
Hb			0.572
< 10	33.1	39.1	
≥ 10	66.9	60.9	
WBC			0.014 [a]
< 4000	19.7	34.8	
≥ 4000	80.3	66.2	
PLT			0.979
< 150000	30.7	30.4	
≥ 150000	69.3	69.6	
C3			0.57
< 80	32.1	39.8	
≥ 80	67.9	61.2	
C4			0.117
< 10	9.5	22.2	
≥ 10	90.5	77.8	
CRP			0.004 [a]
Positive	60.7	27.3	
Negative	39.3	72.7	

Abbreviations: ANA, anti-nuclear antibody; Anti-ds DNA, anti-double strand DNA antibody; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; C3, complement 3; C4, complement 4; CRP, C-Reactive protein.
[a] Significance level: P-value < 0.05.

cantly higher in men than women. (34.8% vs. 19.7%, P = 0.005). However, in the study of Garcia et al. in Latin America, there was no significant difference between men and women in terms of leukopenia (5.7% in men and 5% in women) (17). In another study in Latin America, no significant difference was reported in this regard (the prevalence of leukopenia was 37% in men and 39% in women) (33).

4.1. Conclusions

Due to the variety of clinical symptoms and even laboratory features of SLE in different ethnic groups and geographical areas, it is necessary to pay attention to the disease's typical pattern in each region for its correct diagnosis in suspicious patients. In this study, it was found

that the most common clinical symptom of SLE patients in Kermanshah is blood manifestations; Therefore, if the patient has problems such as anemia or thrombocytopenia or leukopenia, SLE should be suspected and diagnostic tests such as ANA, anti-ds DNA, CRP, C3, C4 should be used to diagnose the disease early and prevent its progression.

Acknowledgments

Footnotes

Authors' Contribution: Z.M. conceived the study and wrote the manuscript. M.N. reviewed the file of patients. A.R. and M.A. critically revised the manuscript. D.P. critically revised the manuscript and provided the final approval.

Conflict of Interests: The authors declare that they have no conflicts of interest regarding this manuscript.

References

1. Akbarian M, Faezi ST, Gharibdoost F, Shahram F, Nadji A, Jamshidi AR, et al. Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. *Int J Rheum Dis*. 2010;**13**(4):374–9. [PubMed ID: 21199473]. https://doi.org/10.1111/j.1756-185X.2010.01547.x.

2. Haghpanah V, Ghaffari SH, Rahimpour P, Abbasi A, Saeedi M, Pak H, et al. Vitamin D receptor gene polymorphisms in patients with thyroid cancer. *Gene Ther Mol Biol B*. 2007;**11**(2):299–304.

3. Bresnihan B. Outcome and survival in systemic lupus erythematosus. *Ann Rheum Dis*. 1989;**48**(6):443–5. [PubMed ID: 2662916]. [PubMed Central ID: PMC1003784]. https://doi.org/10.1136/ard.48.6.443.

4. Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. *Arthritis Rheum*. 1982;**25**(1):55–60. [PubMed ID: 6978135]. https://doi.org/10.1002/art.1780250109.

5. Wang L, Yang Y, Lu M, Chiang B. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. *J Microbiol Immunol Infect*. 2003;**36**(3):203–8.

6. Mok CC, Lau CS, Chan TM, Wong RW. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. *Lupus*. 1999;**8**(3):188–96. [PubMed ID: 10342711]. https://doi.org/10.1191/096120399678847605.

7. Utz PJ. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. *Lupus*. 2004;**13**(5):304–11. [PubMed ID: 15230283]. https://doi.org/10.1191/0961203303lu1017oa.

8. Uramoto KM, Michet Jr CJ, Thumboo J, Sunku J, O'Fallon W, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. *Arthritis Rheumatol*. 1999;**42**(1):46–50. https://doi.org/10.1002/1529-0131(199901)42:1<46::Aid-anr6>3.0.Co;2-2.

9. Schumacher H, Bardin T. The spondylarthropathies: Classification and diagnosis. Do we need new terminologies? *Baillière's Clin Rheumatol*. 1998;**12**(4):551–65. https://doi.org/10.1016/s0950-3579(98)80037-x.

10. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med*. 2005;**142**(12_Part_1):953–62.

11. Lahita RG. The role of sex hormones in systemic lupus erythematosus. *Curr Opin Rheumatol*. 1999;**11**(5):352–6. [PubMed ID: 10503654]. https://doi.org/10.1097/00002281-199909000-00005.

12. Seyed Bonakdar Z, Nasiri S, Karimifar M, Karimzadeh H, Salesi M, Motaghi P. [Clinical and Laboratory Signs among Systemic Lupus Erythematosus Patients in Isfahan]. *J Isfahan Med Sch*. 2012;**29**(164). Persian.

13. Akbarian M, Faezi ST, Gharibdoost F, Shahram F, Nadji A, Jamshidi AR, et al. The epidemiology of systemic lupus erythematosus in Iran: a survey on 2143 cases. *Tehran Univ Med J*. 2010;**68**(5).

14. Aringer M. EULAR/ACR classification criteria for SLE. *Semin Arthritis Rheum*. 2019;**49**(3):14–7. https://doi.org/10.1016/j.semarthrit.2019.09.009.

15. Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. *Curr Opin Rheumatol*. 2005;**17**(5):568–73. [PubMed ID: 16093835]. https://doi.org/10.1097/01.bor.0000169364.69066.1e.

16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum*. 1980;**23**(2):137–45. [PubMed ID: 7362664]. https://doi.org/10.1002/art.1780230202.

17. Garcia MA, Marcos JC, Marcos AI, Pons-Estel BA, Wojdyla D, Arturi A, et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. *Lupus*. 2005;**14**(12):938–46. [PubMed ID: 16425573]. https://doi.org/10.1191/0961203305lu2245oa.

18. Chang DM, Chang CC, Kuo SY, Chu SJ, Chang ML. The clinical features and prognosis of male lupus in Taiwan. *Lupus*. 1998;**7**(7):462–8. [PubMed ID: 9796848]. https://doi.org/10.1191/096120398678920479.

19. Yaghoubi A, Fathi ZH. [Cutaneous manifestations of systemic Lupus Erythematosus: A study from Ahwaz]. *Iran J Dermatology*. 1379;**3**(11):35–41. Persian.

20. Faezi ST, Hosseini Almodarresi M, Akbarian M, Gharibdoost F, Akhlaghi M, Jamshidi A, et al. Clinical and immunological pattern of systemic lupus erythematosus in men in a cohort of 2355 patients. *Int J Rheum Dis*. 2014;**17**(4):394–9. [PubMed ID: 24618453]. https://doi.org/10.1111/1756-185X.12268.

21. Roth RS, Geisser ME. Educational achievement and chronic pain disability: mediating role of pain-related cognitions. *Clin J Pain*. 2002;**18**(5):286–96. [PubMed ID: 12218499]. https://doi.org/10.1097/00002508-200209000-00003.

22. Dickens C, Jayson M, Creed F. Psychological correlates of pain behavior in patients with chronic low back pain. *Psychosomatics*. 2002;**24**(1):42–8. [PubMed ID: 11927757]. https://doi.org/10.1176/appi.psy.43.1.42.

23. Tabarestani M, Hatef MR, Keramati MR. [Hematologie manifestations in systemic luplls erythematosus]. *Med J Mashhad Univ Med Sci*. 2003;**45**(78):5–12. Persian.

24. Namian AM, Rahiminejad M. [Laboratory findings in discoid lupus erythematosus: A study on 51 patients in skin clinic of Shahid Faghihi hospital, Shiraz, 1998 - 2000]. *Iran J Dermatology*. 2001;**4**(3):3–19. Persian.

25. Maloney KC, Ferguson TS, Stewart HD, Myers AA, De Ceulaer K. Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis. *Lupus*. 2017;**26**(13):1448–56. [PubMed ID: 28480787]. https://doi.org/10.1177/0961203317707828.

26. Kelley W. Systemic lupus erythematosus and related syndromes. In: Virgil LWJ, editor. *Textbook of Rheumatology, William N. Kelley*. 2nd ed. Philadelphia, WB: Saunders; 1989.

27. Amini OR, Rezazadeh M, Shakibi MR, Cheheltanan M. *Epidemiologic evaluation the SLE patients referred to Kerman clinics of rheumatology [Thesis]*. Afzalipour Med Univ; 2007.

28. Qari Faiza A. Clinical pattern of systemic lupus erythematosus in Western Saudi Arabia. *Saudi Med J*. 2002;**23**(10):1247–50.

29. Adei M, Moula K, Saraj M, Halabian M, Ghaderian B. Evaluation of relation between cardiac disease and anti-cardiolipin antibody in inactive lupus patients. *J Isfahan Med Sch*. 2004.

30. Saghafi M, Forughipour M, Rezayi Yazdi Z, Sakhdari A. [Neuropsychiatric manifestations in patients with systemic lupus erythematosus]. *J mashhad Univ Med Sci*. 2007;**50**(4):355–60. Persian.

31. Font J, Cervera R, Navarro M, Pallares L, Lopez-Soto A, Vivancos J, et al. Systemic lupus erythematosus in men: clinical and immunological characteristics. *Ann Rheum Dis*. 1992;**51**(9):1050–2. [PubMed ID: 1417135]. [PubMed Central ID: PMC1004835]. https://doi.org/10.1136/ard.51.9.1050.

32. Ebrahimpour M, Faezi ST, Akbarian M, Akhlaghi M, Kheiyrandish M, Shahali A, et al. [Clinical and preclinical manifestation of systemic lupus erythmatous]. *Hormozgan Med J*. 2011;**15**(1):33–9. Persian.

33. Molina JF, Drenkard C, Molina J, Cardiel MH, Uribe O, Anaya JM, et al. Systemic lupus erythematosus in males. A study of 107 Latin American patients. *Medicine (Baltimore)*. 1996;**75**(3):124–30. [PubMed ID: 8965681]. https://doi.org/10.1097/00005792-199605000-00002.